{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:41:39Z","timestamp":1781779299370,"version":"3.54.5"},"reference-count":30,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:p>Background: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for the treatment of relapsing multiple sclerosis. Flushing and gastrointestinal (GI) adverse events (AEs) are common within the first few months of starting DMF therapy. Although most symptoms are mild or moderate in severity, transient, and infrequently result in treatment discontinuation, they nevertheless present a challenge for patients to adhere to therapy and achieve an optimal treatment response.<\/jats:p><jats:p>Methods: This review discusses management strategies for the prophylaxis and treatment of common DMF-associated AEs based on clinical trial evidence and real-world experience in clinical practice settings.<\/jats:p><jats:p>Results: Before starting DMF therapy, patients should receive counseling on the importance of treatment adherence and the likely occurrence and severity of flushing and GI AEs (nausea, vomiting, diarrhea, and abdominal pain). Management strategies, such as administering DMF with food, using a slower-dose titration schedule, applying temporary dose reductions, and using symptomatic therapies, provide clinicians with several approaches to address DMF tolerability. In particular, DMF coadministration with certain foods (eg, sausage, peanut butter) may prevent or reduce the severity of GI AEs. Taking aspirin 325 mg\/day 30 minutes before administering DMF in the first month of therapy can reduce the incidence and severity of flushing without negatively affecting GI-related events.<\/jats:p><jats:p>Conclusions: Through continual patient education and support and management of treatment-related flushing and GI AEs, clinicians can help patients adhere to and persist with DMF therapy, thus maximizing treatment benefit.<\/jats:p>","DOI":"10.7224\/1537-2073.2015-086","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T15:31:12Z","timestamp":1465831872000},"page":"74-83","source":"Crossref","is-referenced-by-count":25,"title":["Dimethyl Fumarate"],"prefix":"10.7224","volume":"19","author":[{"given":"J. Theodore","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Agrella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","reference":[{"key":"2020060301053196700_i1537-2073-19-2-74-b1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"2020060301053196700_i1537-2073-19-2-74-b2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"2020060301053196700_i1537-2073-19-2-74-b3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur J Neurol"},{"key":"2020060301053196700_i1537-2073-19-2-74-b4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin Drug Investig"},{"key":"2020060301053196700_i1537-2073-19-2-74-b5","article-title":"Summary of product characteristics: Tecfidera 120 mg gastro-resistant hard capsules","author":"European Medicines Agency"},{"key":"2020060301053196700_i1537-2073-19-2-74-b6","volume-title":"Tecfidera (dimethyl fumarate) delayed-release capsules [prescribing information]","year":"2015"},{"key":"2020060301053196700_i1537-2073-19-2-74-b7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"2020060301053196700_i1537-2073-19-2-74-b8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"2020060301053196700_i1537-2073-19-2-74-b9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","article-title":"Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE)","volume":"18","author":"Fox","year":"2016","journal-title":"Int J MS Care"},{"key":"2020060301053196700_i1537-2073-19-2-74-b10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","article-title":"Clinical significance of gastrointestinal and flushing events in MS patients treated with delayed-release dimethyl fumarate","volume":"17","author":"Phillips","year":"2015","journal-title":"Int J MS Care"},{"key":"2020060301053196700_i1537-2073-19-2-74-b11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/acn3.148","article-title":"Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials","volume":"2","author":"Viglietta","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"2020060301053196700_i1537-2073-19-2-74-b12","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.clinthera.2014.08.013","article-title":"Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies","volume":"36","author":"Kita","year":"2014","journal-title":"Clin Ther"},{"key":"2020060301053196700_i1537-2073-19-2-74-b13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1352458514537013","article-title":"Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)","volume":"21","author":"Gold","year":"2015","journal-title":"Mult Scler"},{"issue":"suppl 14","key":"2020060301053196700_i1537-2073-19-2-74-b14","article-title":"Efficacy of delayed-release dimethyl fumarate for RRMS in prior interferon users in the DEFINE and CONFIRM studies","volume":"84","author":"Fernandez","year":"2015","journal-title":"Neurology"},{"key":"2020060301053196700_i1537-2073-19-2-74-b15","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","author":"Gold","journal-title":"Mult Scler"},{"key":"2020060301053196700_i1537-2073-19-2-74-b16","article-title":"Efficacy of delayed-release dimethyl fumarate vs glatiramer acetate on a novel composite outcome measure of inflammatory disease activity: post-hoc analysis of the CONFIRM study","author":"Kremenchutzky"},{"key":"2020060301053196700_i1537-2073-19-2-74-b17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate\u2013treated MS patients: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"2020060301053196700_i1537-2073-19-2-74-b18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40120-015-0033-1","article-title":"Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience","volume":"4","author":"Gold","year":"2015","journal-title":"Neurol Ther"},{"key":"2020060301053196700_i1537-2073-19-2-74-b19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.msard.2014.03.003","article-title":"Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel","volume":"3","author":"Phillips","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"2020060301053196700_i1537-2073-19-2-74-b20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","article-title":"Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study","volume":"4","author":"Phillips","year":"2015","journal-title":"Neurol Ther"},{"key":"2020060301053196700_i1537-2073-19-2-74-b21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1185\/03007990802569455","article-title":"A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events","volume":"25","author":"Brandes","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2020060301053196700_i1537-2073-19-2-74-b22","article-title":"Individualized patient counselling can improve adherence by efficient management of avoidable adverse events","author":"M\u00e4urer"},{"key":"2020060301053196700_i1537-2073-19-2-74-b23","article-title":"Adherence project with German MS-patients: can an approach of individualized patient counseling improve adherence","author":"M\u00e4urer"},{"key":"2020060301053196700_i1537-2073-19-2-74-b24","doi-asserted-by":"crossref","article-title":"Dimethyl fumarate tolerability and treatment adherence amongst patients with multiple sclerosis enrolled in specialty pharmacy services","author":"Holliday","DOI":"10.1212\/WNL.82.10_supplement.P2.230"},{"key":"2020060301053196700_i1537-2073-19-2-74-b25","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.clinthera.2015.03.028","article-title":"Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate","volume":"37","author":"O'Gorman","year":"2015","journal-title":"Clin Ther"},{"key":"2020060301053196700_i1537-2073-19-2-74-b26","article-title":"Strategies to reduce adverse events related to oral dimethyl fumarate","author":"Sammarco"},{"key":"2020060301053196700_i1537-2073-19-2-74-b27","article-title":"Effect of bismuth subsalicylate on gastrointestinal events associated with delayed-release dimethyl fumarate: a double-blind, placebo-controlled study","author":"Tornatore"},{"key":"2020060301053196700_i1537-2073-19-2-74-b28","doi-asserted-by":"crossref","article-title":"Effect of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving delayed-release dimethyl fumarate: a multicenter, randomized, double-blind, placebo-controlled study (MITIGATE)","author":"Tornatore","DOI":"10.1212\/WNL.84.14_supplement.P1.127"},{"key":"2020060301053196700_i1537-2073-19-2-74-b29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.clinthera.2013.08.009","article-title":"Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers","volume":"35","author":"Sheikh","year":"2013","journal-title":"Clin Ther"},{"key":"2020060301053196700_i1537-2073-19-2-74-b30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.msard.2015.07.007","article-title":"Optimizing therapy early in multiple sclerosis: an evidence-based view","volume":"4","author":"Ziemssen","year":"2015","journal-title":"Mult Scler Relat Disord"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/19\/2\/74\/2090471\/1537-2073_2015-086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/19\/2\/74\/2090471\/1537-2073_2015-086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:42Z","timestamp":1752786762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/dimethyl-fumarate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2015-086","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}